CELU
Price
$1.85
Change
-$0.06 (-3.14%)
Updated
Jun 27 closing price
Capitalization
44.31M
SPRO
Price
$2.94
Change
+$0.04 (+1.38%)
Updated
Jun 27 closing price
Capitalization
164.38M
38 days until earnings call
Interact to see
Advertisement

CELU vs SPRO

Header iconCELU vs SPRO Comparison
Open Charts CELU vs SPROBanner chart's image
Celularity
Price$1.85
Change-$0.06 (-3.14%)
Volume$19.96K
Capitalization44.31M
Spero Therapeutics
Price$2.94
Change+$0.04 (+1.38%)
Volume$1.69M
Capitalization164.38M
CELU vs SPRO Comparison Chart in %
Loading...
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELU vs. SPRO commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELU is a Buy and SPRO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CELU: $1.85 vs. SPRO: $2.94)
Brand notoriety: CELU and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELU: 27% vs. SPRO: 30%
Market capitalization -- CELU: $44.31M vs. SPRO: $164.38M
CELU [@Biotechnology] is valued at $44.31M. SPRO’s [@Biotechnology] market capitalization is $164.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELU’s FA Score shows that 0 FA rating(s) are green whileSPRO’s FA Score has 1 green FA rating(s).

  • CELU’s FA Score: 0 green, 5 red.
  • SPRO’s FA Score: 1 green, 4 red.
According to our system of comparison, SPRO is a better buy in the long-term than CELU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELU’s TA Score shows that 3 TA indicator(s) are bullish while SPRO’s TA Score has 5 bullish TA indicator(s).

  • CELU’s TA Score: 3 bullish, 6 bearish.
  • SPRO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SPRO is a better buy in the short-term than CELU.

Price Growth

CELU (@Biotechnology) experienced а +5.11% price change this week, while SPRO (@Biotechnology) price change was -2.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

SPRO is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SPRO($164M) has a higher market cap than CELU($44.3M). SPRO YTD gains are higher at: 185.437 vs. CELU (-11.058). CELU has higher annual earnings (EBITDA): -21.59M vs. SPRO (-73.06M). SPRO has more cash in the bank: 48.9M vs. CELU (133K). SPRO has less debt than CELU: SPRO (3.96M) vs CELU (69.1M). CELU has higher revenues than SPRO: CELU (48.2M) vs SPRO (28.3M).
CELUSPROCELU / SPRO
Capitalization44.3M164M27%
EBITDA-21.59M-73.06M30%
Gain YTD-11.058185.437-6%
P/E RatioN/A10.75-
Revenue48.2M28.3M170%
Total Cash133K48.9M0%
Total Debt69.1M3.96M1,745%
FUNDAMENTALS RATINGS
CELU vs SPRO: Fundamental Ratings
CELU
SPRO
OUTLOOK RATING
1..100
5450
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
6434
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELU's Valuation (54) in the null industry is in the same range as SPRO (59) in the Pharmaceuticals Major industry. This means that CELU’s stock grew similarly to SPRO’s over the last 12 months.

CELU's Profit vs Risk Rating (100) in the null industry is in the same range as SPRO (100) in the Pharmaceuticals Major industry. This means that CELU’s stock grew similarly to SPRO’s over the last 12 months.

SPRO's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as CELU (99) in the null industry. This means that SPRO’s stock grew similarly to CELU’s over the last 12 months.

SPRO's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as CELU (64) in the null industry. This means that SPRO’s stock grew similarly to CELU’s over the last 12 months.

SPRO's P/E Growth Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for CELU (100) in the null industry. This means that SPRO’s stock grew significantly faster than CELU’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELUSPRO
RSI
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 3 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
72%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
76%
Advances
ODDS (%)
N/A
Bullish Trend 10 days ago
71%
Declines
ODDS (%)
Bearish Trend 17 days ago
81%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WT11.420.31
+2.79%
WisdomTree
KO70.330.86
+1.24%
Coca-Cola Company
FATBB2.47N/A
N/A
FAT Brands
SMC25.77-0.07
-0.27%
Summit Midstream Corporation
WTFC123.32-0.89
-0.72%
Wintrust Financial Corp

CELU and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELU has been loosely correlated with ACOG. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CELU jumps, then ACOG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELU
1D Price
Change %
CELU100%
-3.14%
ACOG - CELU
48%
Loosely correlated
-1.14%
NVCT - CELU
27%
Poorly correlated
-2.08%
CYBN - CELU
26%
Poorly correlated
-5.01%
SPRO - CELU
26%
Poorly correlated
+1.38%
OTLK - CELU
25%
Poorly correlated
-8.57%
More

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with ASBP. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then ASBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
+1.38%
ASBP - SPRO
62%
Loosely correlated
-7.03%
CLGN - SPRO
43%
Loosely correlated
+0.36%
ITOS - SPRO
35%
Loosely correlated
-0.60%
XENE - SPRO
32%
Poorly correlated
+0.62%
SYRE - SPRO
31%
Poorly correlated
-4.99%
More